| 查看: 1001 | 回复: 1 | |||
1006939364木虫 (正式写手)
|
[求助]
[求助]他达拉非的理化性质
|
求助他达拉非的理化性质，有大神帮忙查一下吗？默克和贝尔斯坦的都可以，最好能够很全。比如溶解度，酸碱性等等！谢谢 |
回复此楼» 猜你喜欢
一志愿武汉理工，总分321，英一数二，求老师收留。
已经有5人回复
-
324求调剂
已经有8人回复
-
284求调剂
已经有12人回复
-
348求调剂
已经有3人回复
-
329求调剂
已经有7人回复
-
求调剂，一志愿 南京航空航天大学大学 ，080500材料科学与工程学硕
已经有4人回复
-
考研调剂
已经有9人回复
-
304材料求调剂
已经有4人回复
-
一志愿郑大085600，310分求调剂
已经有3人回复
-
317求调剂
已经有7人回复
baiyuefei
版主 (文学泰斗)
风雪
- 应助: 4642 (副教授)
- 贵宾: 46.969
- 金币: 658106
- 散金: 11616
- 红花: 995
- 沙发: 81
- 帖子: 69424
- 在线: 13328.4小时
- 虫号: 676696
- 注册: 2008-12-18
- 性别: GG
- 专业: 合成药物化学
- 管辖: 有机交流
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
感谢参与，应助指数 +1
1006939364(心静_依然代发): 金币+40, 感谢应助 2015-05-24 10:07:20
感谢参与，应助指数 +1
1006939364(心静_依然代发): 金币+40, 感谢应助 2015-05-24 10:07:20
|
默克 Tadalafil Back to search results Add to My Records Print view Monograph ID: M10427 Title: Tadalafil CAS Registry Number: 171596-29-5 CAS Name: (6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1′,2′:1,6]‐pyrido[3,4-b]indole-1,4-dione Additional Names: (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-[3,4-(methylenedioxy)phenyl]pyrazino[1′,2′:1,6]‐pyrido[3,4-b]indole-1,4-dione Manufacturer Code: GF-196960; IC-351 Trademark Names: Adcirca (Lilly); Cialis (Lilly) Molecular Formula: C22H19N3O4 Molecular Weight: 389.41 Percent Composition: C 67.86%, H 4.92%, N 10.79%, O 16.43% Standard InChI: InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1Copy Copied Standard InChIKey: WOXKDUGGOYFFRN-IIBYNOLFSA-NCopy Copied Properties White crystals from 2-propanol, mp 302-303 °C. [α]D20 +71.0 (c = 1.00 in CHCl3). Very slightly sol in ethanol. Practically insol in water. References Selective type 5 cGMP phosphodiesterase (PDE-5) inhibitor. Prepn: A. C. Daugan, WO 9519978 (1995 to Glaxo); eidem, US 5859006 (1999 to ICOS); and PDE-5 inhibition: idem et al., J. Med. Chem. 46, 4525, 4533 (2003) DOI: 10.1021/jm030056e PMID: 14521414. HPLC determn in plasma: C.-L. Cheng, C.-H. Chou, J. Chromatogr. B 822, 278 (2005) DOI: 10.1016/j.jchromb.2005.06.017. Clinical pharmacokinetics: S. T. Forgue et al., Br. J. Clin. Pharmacol. 61, 280 (2005) DOI: 10.1111/j.1365-2125.2005.02553.x PMID: 16487221. Clinical comparison with sildenafil for erectile disfunction: I. Eardley et al., BJU Int. 96, 1323 (2005) DOI: 10.1111/j.1464-410X.2005.05892.x PMID: 16287454. Clinical trial in pulmonary arterial hypertension: N. Galié et al., Circulation 119, 2894 (2009) DOI: 10.1161/CIRCULATIONAHA.108.839274 PMID: 19470885. Review of cardiovascular effects: T. Reffelmann et al., Expert Opin. Drug Saf. 7, 43-52 (2008) DOI: 10.1517/14740338.7.1.43 PMID: 18171313. Classifications Therapeutic Category: Erectile Dysfunction Treatment; Phosphodiesterase Inhibitor; Pulmonary Hypertension Treatment Keywords: In treatment of male erectile dysfunction. In treatment of pulmonary arterial hypertension. Save image Save structure Other RSC ContentPowered by ChemSpider ChemSpider Record ChemSpider Structure Search Search RSC Publications |
2楼2015-05-20 14:29:04
6